Compare Applovin Corporation (APP) vs TG Therapeutics Inc (TGTX) Price & Performance

AppLovin (APP) trades at $310.95, down 8.27% over 24 hours, reflecting recent bearish momentum after a Q2 2026 earnings miss. The stock shows strong profitability with a 64.58% net income margin and robust revenue growth of 53% YoY in Q2, but faces technical pressure with a bearish signal from moving averages. Recent news highlights a Bank of America downgrade to Neutral on August 11, 2026, citing uncertainty around sustaining 30% revenue growth, contributing to the stock's decline.

The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest upside, but execution risks and technical weakness pose near-term challenges. Investors should weigh high valuation multiples against growth sustainability concerns.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.